Project Grant R01CA308427
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $697K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $147,083 Project Grant to Icahn School of Medicine at Mount Sinai under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. This award supports mentored postdoctoral research training through an NCI Pathway to Independence Award (K99/R00) mechanism, funding a career development project titled "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69M Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion targeted for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of neuregulin 3 (NRG3) induction in bone metastasis, with the objective of advancing understanding of how breast cancer cells preferentially...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $708,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. The grant supports fundamental research investigating the microenvironmental and hepatocyte cell type-specific regulation of colorectal cancer (CRC) metastasis by the IL17 cytokine. The research aims to elucidate how IL17 signaling in hepatocytes and myeloid...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $323,860 under the Cancer Research Manpower program (CFDA 93.398), effective August 18, 2025, with completion by April 30, 2028. This award supports investigative research to elucidate the role of mutagenic DNA repair mechanisms, specifically microhomology-mediated end joining (MMEJ), during cancer cell persistence and the development of acquired drug...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...